Dynavax to Present New Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) at the European Society for Medical Onc...
October 09 2018 - 6:00AM
Dynavax Technologies Corporation (NASDAQ:DVAX) announced today that
data will be presented from its ongoing Phase 1b/2 study
investigating SD-101, Dynavax's intratumoral TLR9 agonist, in
combination with KEYTRUDA® (pembrolizumab), an anti-PD-1 therapy
developed by Merck (known as MSD outside the United States and
Canada). Data will be presented in three individual sessions with
data for advanced melanoma patients who are naïve to anti-PD-1
therapy being presented as a late-breaking abstract poster
discussion, at the European Society for Medical Oncology (ESMO)
2018 Congress, being held October 19-23, 2018 in Munich
Germany.
The details of the poster presentations and discussion sessions
are as follows:
Phase Ib/II, open label, multicenter study of
intratumoral SD-101 in combination with pembrolizumab in anti-PD-1
treatment naïve patients with recurrent or metastatic head and neck
squamous cell carcinoma (HNSCC)
Poster Discussion Session: Head and Neck CancersFinal
Publication Number: 1050PDDiscussion Session Date/Time: Saturday,
October 20, 2018, 3:00 PM - 4:15 PM
CEST
Discussion Session Location: Hall B3 - Room 23, ICM München,
Munich GermanyPoster Session Date/Time: Saturday, October 20, 9:00
AM CEST to Monday, October 22, 5:00 PM CESTPoster Session Location:
Hall B4 – ICM München, Munich Germany
Phase 1b/2, open label, multicenter, study of the
combination of SD-101 and pembrolizumab in patients with advanced
melanoma who are naïve to anti-PD-1
therapy
Poster Discussion Session: Melanoma and Other Skin TumoursFinal
Publication Number: LBA45Discussion Session Date/Time: Saturday,
October 20, 2018, 2:45 PM - 4:05 PM CESTDiscussion Session
Location: ICM - Room 14b, ICM München, Munich GermanyPoster Session
Date/Time: Saturday, October 20, 2:45 PM CEST to Monday, October
22, 5:00 PM CESTPoster Session Location: Hall B4 – ICM
München, Munich Germany
Phase Ib/II study of the combination of SD-101 and
pembrolizumab in patients with advanced melanoma who had
progressive disease on or after prior anti-PD-1
therapy
Poster Session: Basic science, Endocrine tumours,
Gastrointestinal tumours - colorectal & non-colorectal, Head
and neck cancer (excluding thyroid), Melanoma and other skin
tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology
& pathologyFinal Publication Number: 1265PPoster Session
Date/Time: Sunday, October 21, 12:45 PM - 1:45 PM CESTPoster
Session Location: Hall A3 – Poster Area Networking Hub, ICM
München, Munich Germany
About SD-101SD-101, the Company's lead clinical
candidate, is a proprietary, second-generation, Toll-like receptor
9 (TLR9) agonist CpG-C class oligodeoxynucleotide. Dynavax is
evaluating this intratumoral TLR9 agonist in several clinical
studies to assess its safety and activity, including a Phase 2
study in combination with KEYTRUDA® (pembrolizumab), an anti-PD-1
therapy, in patients with advanced melanoma and in patients with
head and neck squamous cell cancer, in a clinical collaboration
with Merck. Dynavax maintains all commercial rights to SD-101.
About DynavaxDynavax is a fully-integrated
biopharmaceutical company focused on leveraging the power of the
body's innate and adaptive immune responses through toll-like
receptor (TLR) stimulation. Dynavax discovers and develops novel
vaccines and immuno-oncology therapeutics. The Company launched its
first commercial product, HEPLISAV-B® [Hepatitis B Vaccine
(Recombinant), Adjuvanted], in January 2018, following U.S. FDA
approval for prevention of infection caused by all known subtypes
of hepatitis B virus in adults age 18 years and older. Dynavax's
lead immunotherapy product, SD-101, is an investigational cancer
immunotherapeutic currently being evaluated in Phase 1/2 studies
and its second cancer immunotherapeutic, DV281, is in Phase 1
development. For more information, visit www.dynavax.com.
KEYTRUDA is a registered trademark of Merck Sharp & Dohme
Corp., a subsidiary of Merck & Co., Inc.
Contact: Ryan SpencerVice
President, Corporate Strategy and Communications510.665.4618
|
Media Contact:Rachel St.
MartinW2O 646.894.5757 rstmartin@w2ogroup.com
|
Dynavax Technologies (NASDAQ:DVAX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dynavax Technologies (NASDAQ:DVAX)
Historical Stock Chart
From Apr 2023 to Apr 2024